On this day, the stock price of Celltrion is going between 380,000 won (-1.04% compared to the previous day) and 387,000 won (+0.78%).
This year, Celltrion continued to rise, rising 10.50% based on the closing price from the 4th to the previous day. On December 29, last year, the Ministry of Food and Drug Safety applied for conditional approval based on the results of phase 2 clinical trials of Rekirona, and this seems to have reflected the expectation of approval for the first domestic COVID-19 treatment.
However, while Celltrion applied for conditional approval for Rekirona, it did not disclose specific clinical data, which led to some criticism. However, the non-disclosure of clinical data was at the request of the Ministry of Food and Drug Safety, which felt burdened by the focus of attention on the treatment for Corona 19.
In phase 1 clinical trials for Rekirona, where the data were previously disclosed, it was confirmed that the effect of shortening the recovery period of patients with mild Corona 19 by about 44%.
Celltrion R&D Director Kwon Ki-sung attended a discussion meeting jointly held by Democrats Lee Gwang-jae, Hwang-hee, and Shin Hyun-young at the National Assembly the day before, and said, “Compared to the antibody treatments of Lily and Regeneron, we got more than equivalent results.” Prior to this, Lily and Regeneron each received emergency approval for COVID-19 antibody treatment from the US Food and Drug Administration (FDA).
Rekirona is a drug developed to produce a cell line for mass production after selecting antibodies that will block the corona 19 virus from the blood of a cure for Corona 19.
[한경우 매경닷컴 기자 [email protected]]
[ⓒ 매일경제 & mk.co.kr, 무단전재 및 재배포 금지]